Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Cerilliant
US Department of Justice
Harvard Business School
Federal Trade Commission
Colorcon
QuintilesIMS
Boehringer Ingelheim
Covington
Julphar

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,605,300

« Back to Dashboard

Summary for Patent: 6,605,300
Title: Oral pulsed dose drug delivery system
Abstract:A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
Inventor(s): Burnside; Beth A. (Silver Spring, MD), Guo; Xiaodi (Derwood, MD), Fiske; Kimberly (Alexandria, VA), Couch; Richard A. (Bethesda, MD), Treacy; Donald J. (Arnold, MD), Chang; Rong-Kun (Hockessin, DE), McGuinness; Charlotte M. (Bethesda, MD), Rudnic; Edward M. (North Potomac, MD)
Assignee: Shire Laboratories, Inc. (Rockville, MD)
Application Number:09/807,462
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Delivery;

Drugs Protected by US Patent 6,605,300

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire ADDERALL XR 10 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-001 Oct 11, 2001 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Shire ADDERALL XR 15 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-006 May 22, 2002 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Shire ADDERALL XR 20 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-002 Oct 11, 2001 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Shire ADDERALL XR 25 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-004 May 22, 2002 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Shire ADDERALL XR 30 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-003 Oct 11, 2001 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Shire ADDERALL XR 5 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-005 May 22, 2002 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,605,300

PCT Information
PCT FiledOctober 20, 1999PCT Application Number:PCT/US99/24554
PCT Publication Date:April 27, 2000PCT Publication Number: WO00/23055

Non-Orange Book US Patents Family Members for Patent 6,605,300

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,322,819 Oral pulsed dose drug delivery system ➤ Try a Free Trial
RE41148 Oral pulsed dose drug delivery system ➤ Try a Free Trial
RE42096 Oral pulsed dose drug delivery system ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,605,300

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 427101 ➤ Try a Free Trial
Australia 1214500 ➤ Try a Free Trial
Canada 2348090 ➤ Try a Free Trial
Germany 69940673 ➤ Try a Free Trial
European Patent Office 1123087 ➤ Try a Free Trial
European Patent Office 1977736 ➤ Try a Free Trial
Spain 2323910 ➤ Try a Free Trial
Japan 2002527468 ➤ Try a Free Trial
Japan 2008303223 ➤ Try a Free Trial
World Intellectual Property Organization (WIPO) 0023055 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
McKinsey
Mallinckrodt
Colorcon
Johnson and Johnson
Medtronic
Deloitte
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot